Genmab — September 2019
-
Enig.
-
I er sgu søde - farvede - men søde
-
du er berettiget til dine egne meninger - men ikke dine egne facts
-
Vi nåede over en 1/2 mia...hold da op!
-
Patients on ofatumumab had a relapse rate of 0.1. That’s a single relapse every 10 years, which is quite unheard of,” Bar-Zohar said. “When we looked at the inflammatory rate in the brain with MRI, ofatumumab showed highly significant, almost complete suppression of disease activity as compared to Aubagio
-
Ofatumumab binds to its target in such a way that allows for a relatively low dose of the drug to be used, so if patients need to go off the drug—say to treat an infection—their B cell population recovers quickly, he said: “The recovery takes about half the time as it does with the infused drugs
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind